Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammed Hadi

Internal Medicine Streamwood, IL Medical Doctor

NPI 1427111764 CMS profile 200721

1645 S Green Meadows Blvd, Ste 101, Streamwood, IL 60107

Open in the dashboard

General payments

$5,359

259 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammed Hadi of Streamwood, IL is reported in the CMS Open Payments database as having received $5,359 across 259 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $696 33
2024 General $659 32
2023 General $1,243 56
2022 General $909 44
2021 General $387 21
2020 General $890 45
2019 General $575 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammed Hadi
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mohammed Hadi were reported at $696. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mohammed Hadi Internal Medicine median Middle half National median
2019 $575 $159 $48–$570 $163
2020 $890 $119 $33–$402 $114
2021 $387 $135 $37–$521 $132
2022 $909 $141 $42–$496 $149
2023 $1,243 $149 $45–$519 $160
2024 $659 $154 $47–$537 $164
2025 $696 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,950 91 payments
  2. GlaxoSmithKline, LLC. $749 35 payments
  3. AbbVie, Inc. $491 25 payments
  4. Lilly USA, LLC $371 18 payments
  5. Sumitomo Pharma America, Inc. $270 12 payments
  6. Astellas Pharma US Inc $255 12 payments
  7. Sunovion Pharmaceuticals Inc. $230 9 payments
  8. Novo Nordisk Inc $191 9 payments
  9. Amgen Inc. $151 7 payments
  10. Merck Sharp & Dohme Corporation $127 8 payments
  11. Other $573 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,268 257 payments
  2. Education $91 2 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $733 34 payments
  2. FARXIGA $698 28 payments
  3. GEMTESA $501 21 payments
  4. SYMBICORT $496 19 payments
  5. BREZTRI $443 21 payments
  6. VRAYLAR $442 22 payments
  7. MYRBETRIQ $170 11 payments
  8. AIRSUPRA $165 6 payments
  9. MOUNJARO $157 6 payments
  10. JARDIANCE $146 8 payments
  11. Other $1,781 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 96 drugs

Part D claims

4,823

Median for Internal Medicine: 777

Drug cost

$380,698

Median for Internal Medicine: $73,373

Branded share of claims

23.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 102 $83,698
Januvia Sitagliptin Phosphate Brand 62 $60,619
Eliquis Apixaban Brand 54 $50,984
Ozempic Semaglutide Brand 33 $31,855
Farxiga Dapagliflozin Propanediol Brand 32 $25,266
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 19 $17,041
Dulera Mometasone/Formoterol Brand 31 $13,702
Mounjaro Tirzepatide Brand 14 $13,330
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 15 $12,011
Breo Ellipta Fluticasone/Vilanterol Brand 20 $8,477

The 10 drugs with the highest cost, of 96 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$71,856

Of which drugs: $5,127

Medicare patients

163

Average age 73

Services billed

911

73 women, 90 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 36%
Arthritis 34%
Ischemic heart disease 32%
Depression 25%
Chronic kidney disease 18%
Heart failure 17%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 61 61 $4,827
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 13 13 $278

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $95
$95 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $91
$91 19 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $43
$43 — —
AREXVY
  • GlaxoSmithKline, LLC. $40
$40 — —
JARDIANCE
  • Lilly USA, LLC $29
$29 102 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

259 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record